Shares of Shattuck Labs, Inc. (NASDAQ:STTK – Get Free Report) have earned an average recommendation of “Moderate Buy” from the six research firms that are covering the company, MarketBeat.com reports. Four analysts have rated the stock with a hold recommendation, one has issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $7.50.
Separately, Leerink Partners began coverage on shares of Shattuck Labs in a research report on Monday. They issued an “outperform” rating and a $4.00 target price on the stock.
Get Our Latest Stock Analysis on STTK
Shattuck Labs Stock Performance
Institutional Trading of Shattuck Labs
Large investors have recently bought and sold shares of the business. JPMorgan Chase & Co. boosted its stake in Shattuck Labs by 63.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 27,533 shares of the company’s stock worth $96,000 after purchasing an additional 10,667 shares during the period. Geode Capital Management LLC boosted its stake in Shattuck Labs by 0.9% during the 3rd quarter. Geode Capital Management LLC now owns 912,202 shares of the company’s stock worth $3,184,000 after purchasing an additional 8,133 shares during the period. MetLife Investment Management LLC boosted its stake in Shattuck Labs by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 24,596 shares of the company’s stock worth $86,000 after purchasing an additional 13,859 shares during the period. State Street Corp boosted its stake in Shattuck Labs by 7.8% during the 3rd quarter. State Street Corp now owns 766,410 shares of the company’s stock worth $2,675,000 after purchasing an additional 55,579 shares during the period. Finally, Barclays PLC boosted its stake in Shattuck Labs by 299.5% during the 3rd quarter. Barclays PLC now owns 54,311 shares of the company’s stock worth $189,000 after purchasing an additional 40,717 shares during the period. Institutional investors and hedge funds own 58.74% of the company’s stock.
Shattuck Labs Company Profile
Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.
Featured Stories
- Five stocks we like better than Shattuck Labs
- Stock Analyst Ratings and Canadian Analyst Ratings
- Grocery Outlet Insider and Institutional Buyers Signal Bottom
- Breakout Stocks: What They Are and How to Identify Them
- Consumers Are Cutting Back, But These 3 Stocks Will Stay Strong
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Disney Stock: 4 Key Metrics Validating Its Comeback
Receive News & Ratings for Shattuck Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shattuck Labs and related companies with MarketBeat.com's FREE daily email newsletter.